Orphazyme Tightens FY21 Revenue Outlook
January 19, 2022 at 06:18 AM EST
Orphazyme A/S(NASDAQ: ORPH)expects FY21 sales of DKK 35 million – DKK 37 million, compared to the previous guidance of ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.